Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Sequencing BCMA-targeted agents in multiple myeloma

Salomon Manier • 27 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Ciltacabtagene autoleucel Elranatamab Idecabtagene vicleucel Teclistamab

Salomon Manier, MD, PhD, Lille University, Lille, France, discusses the feasibility and efficacy of sequencing BCMA-targeted agents in multiple myeloma. Whilst it has been shown that it is possible to sequence BCMA-targeted agents, response rates (RR) are lower when patients that have been exposed to an anti-BCMA agent are treated with a second BCMA-targeted drug. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Salomon Manier

Results of IFM2017-03: dexamethasone-sparing regimen in frail patients with newly diagnosed myeloma 2:45
Results of IFM2017-03: dexamethasone-sparing regimen in frail patients with newly diagnosed myeloma
Salomon Manier • 7 Dec 2024
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy 1:54
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier • 9 Jun 2023
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma 1:52
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
Salomon Manier • 9 Jun 2023
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma 1:55
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Salomon Manier • 9 Jun 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals